vida: extract claims from 2026-04-23-science-hedonic-eating-dopamine-glp1

- Source: inbox/queue/2026-04-23-science-hedonic-eating-dopamine-glp1.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Hedonic eating has a specific dopamine circuit substrate that is pharmacologically addressable but the circuit is continuously activated by environmental triggers making behavioral and biological factors inseparable
+confidence: experimental
+source: Zhu et al., Science 2025, Vol. 387, eadt0773
+created: 2026-04-23
+title: The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
+agent: vida
+sourced_from: health/2026-04-23-science-hedonic-eating-dopamine-glp1.md
+scope: causal
+sourcer: Zhenggang Zhu, Scott M. Sternson et al., Janelia Research Campus
+supports: ["Big-Food-companies-engineer-addictive-products-by-hacking-evolutionary-reward-pathways-creating-a-noncommunicable-disease-epidemic-more-deadly-than-the-famines-specialization-eliminated"]
+related: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm", "Big-Food-companies-engineer-addictive-products-by-hacking-evolutionary-reward-pathways-creating-a-noncommunicable-disease-epidemic-more-deadly-than-the-famines-specialization-eliminated"]
+---
+
+# The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
+
+The study identifies the precise neural circuit mediating hedonic eating: periLC_VGLUT2 → VTA_VGAT ⊣ VTA_DA → NAc dopamine. This circuit encodes palatability and drives consumption beyond homeostatic need. GLP-1 receptor agonists work by pharmacologically suppressing this circuit's responsiveness. This finding dissolves the behavioral-biological dichotomy for obesity: what appears as a 'behavioral' pattern (eating highly palatable food despite satiety) is the direct output of a specific dopamine reward circuit. However, the circuit is continuously activated by environmental triggers—engineered food palatability. The implication is that behavioral factors (food environment, food engineering) remain primary DRIVERS even though the mechanism is biological, because they continuously activate the biological system. Pharmacological intervention addresses the circuit but must be continuous because the triggering environment is continuous. This reframes the 'behavioral vs. clinical' debate: they are not competing explanations but different levels of a single causal chain where environmental factors activate biological circuits that produce behavioral patterns.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -17,3 +17,10 @@ related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metaboli
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
 
 A systematic review of ClinicalTrials.gov identified 33 registered trials examining GLP-1 receptor agonists for substance use disorders: 15 for alcohol use disorder, 9 for nicotine/tobacco, 4 for cocaine, 4 for opioid use disorder, and 1 for methamphetamine. The mechanistic basis is shared with obesity treatment: GLP-1 receptors are expressed in the mesolimbic dopamine system (VTA, nucleus accumbens, amygdala) that underlies both hedonic eating and substance addiction. Early clinical evidence supports this mechanism: an RCT showed low-dose semaglutide reduced laboratory alcohol self-administration, drinks per drinking day, and craving in people with AUD. Real-world analysis by Qeadan et al. found that among people with pre-existing SUD, GLP-1 users showed fewer ER visits, hospitalizations, and deaths related to substance use. Animal studies demonstrate GLP-1s lower self-administration of opioids (heroin, fentanyl, oxycodone) and reduce relapse-like behavior. The breadth of the trial pipeline—with semaglutide as the most studied agent (n=15 trials)—indicates this is being taken seriously as a paradigm shift for addiction medicine. However, most OUD data remains in animal models, and human trial results are not yet published. The field is 2-3 years from definitive clinical evidence, making this experimental rather than proven.
+
+
+## Extending Evidence
+
+**Source:** Zhu et al., Science 2025, Vol. 387, eadt0773
+
+The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA → NAc) is the mesolimbic dopamine pathway implicated in addiction. The study shows GLP-1Rs suppress VTADA neuron responsiveness during consumption, providing the specific circuit mechanism for GLP-1's effects on substance use disorders. The tolerance finding (circuit adaptation during repeated treatment) may also explain variable efficacy in addiction trials.

domains/health/hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: GLP-1 receptor agonists suppress VTADA neuron activity during food consumption reducing hedonic eating but mice recover palatable food appetite during repeated treatment through circuit adaptation
+confidence: experimental
+source: Zhu et al., Science 2025, Vol. 387, eadt0773
+created: 2026-04-23
+title: Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
+agent: vida
+sourced_from: health/2026-04-23-science-hedonic-eating-dopamine-glp1.md
+scope: causal
+sourcer: Zhenggang Zhu, Scott M. Sternson et al., Janelia Research Campus
+related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+---
+
+# Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
+
+Researchers at Janelia Research Campus identified the specific neural circuit controlling hedonic eating: peri-locus ceruleus → ventral tegmental area dopamine neurons → nucleus accumbens. VTADA neurons encode palatability and bidirectionally regulate hedonic food consumption. Critically, semaglutide suppressed VTADA neuron responsiveness during food consumption, reducing hedonic eating. However, during repeated semaglutide treatment, mice recovered palatable food appetite and VTADA neuron activity returned to baseline levels. This recovery was reversed only by direct inhibition of VTADA neurons during consumption. This tolerance finding provides the mechanistic explanation for why GLP-1 receptor agonists require continuous delivery: the biological reward system adapts to pharmacological suppression, and the compulsion reasserts itself. The drug suppresses the circuit, but the circuit adapts and recovers function despite ongoing treatment. This is not a failure of patient adherence but an adaptive biological response at the circuit level.

domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md

@@ -1,16 +1,14 @@
 ---
 type: claim
 domain: health
-description: "Commonwealth Fund's 2024 international comparison shows US last overall among 10 peer nations despite ranking second in care process quality, proving structural failures override clinical excellence"
+description: Commonwealth Fund's 2024 international comparison shows US last overall among 10 peer nations despite ranking second in care process quality, proving structural failures override clinical excellence
 confidence: proven
-source: "Commonwealth Fund Mirror Mirror 2024 report (Blumenthal et al, 2024-09-19)"
+source: Commonwealth Fund Mirror Mirror 2024 report (Blumenthal et al, 2024-09-19)
 created: 2026-03-11
-supports:
+supports: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity"]
-- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07"]
-reweave_edges:
+sourced_from: ["inbox/archive/health/2024-09-19-commonwealth-fund-mirror-mirror-2024.md"]
-- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
+related: ["us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "nhs-demonstrates-universal-coverage-without-adequate-funding-produces-excellent-primary-care-but-catastrophic-specialty-access", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
-sourced_from:
-- inbox/archive/health/2024-09-19-commonwealth-fund-mirror-mirror-2024.md
 ---
 
 # US healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
@@ -57,3 +55,9 @@ Relevant Notes:
 
 Topics:
 - domains/health/_map
+
+## Extending Evidence
+
+**Source:** OECD Health at a Glance 2025, US country profile
+
+OECD 2025 shows US clinical quality is not just adequate but world-leading for acute care (30-day AMI mortality 5.2% vs. OECD 6.5%, stroke 4.5% vs. 7.7%). The ranking failure is driven by preventable mortality (50% worse than OECD) and treatable mortality (23% worse despite highest spending), indicating the problem is prevention infrastructure and access to existing excellent care, not clinical capability.

domains/health/us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "International comparison shows US excels at clinical intervention (AMI/stroke mortality 21% better than OECD) while failing at prevention (preventable mortality 50% worse), despite spending 2.5x the OECD average"
+confidence: proven
+source: OECD Health at a Glance 2025, United States country profile
+created: 2026-04-23
+title: The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health
+agent: vida
+sourced_from: health/2026-04-23-oecd-health-at-a-glance-2025-us.md
+scope: causal
+sourcer: OECD
+supports: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm"]
+related: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
+---
+
+# The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health
+
+The US spends $14,885 per capita on healthcare (2.5x the OECD average of $5,967) and 17.2% of GDP (vs. OECD average 9.3%), yet achieves life expectancy 4.3 years below peer countries (78.4 vs. 82.7 years). The critical finding is the SPLIT in outcomes: the US outperforms on acute clinical care — 30-day AMI mortality is 5.2% vs. OECD average 6.5% (21% better), and 30-day stroke mortality is 4.5% vs. 7.7% (42% better). However, preventable mortality (deaths from conditions where behavioral/environmental intervention works) is 217 per 100,000 vs. OECD average 145 (50% worse), and treatable mortality (deaths where timely clinical care should save lives) is 95 vs. 77 (23% worse). This pattern is exactly what the non-clinical factors hypothesis predicts: excellent clinical performance cannot compensate for structural failures in the behavioral, social, and environmental determinants of health. The US system is optimized for — and excels at — clinical intervention, but this is the wrong lever for improving population health outcomes. The spending is directed almost entirely at clinical care, with minimal investment in prevention and social infrastructure, creating a system that is world-class at treating disease but catastrophically bad at preventing it. The 23% worse treatable mortality despite being the highest spender also suggests access failures prevent even the excellent clinical care from reaching all populations.

inbox/archive/health/2026-04-23-oecd-health-at-a-glance-2025-us.md

@@ -7,9 +7,12 @@ date: 2025-11-01
 domain: health
 secondary_domains: []
 format: statistical report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: high
 tags: [OECD, international-comparison, health-spending, outcomes, life-expectancy, preventable-mortality, clinical-effectiveness, US-health-system]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-23-science-hedonic-eating-dopamine-glp1.md

@@ -7,9 +7,12 @@ date: 2025-03-01
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: high
 tags: [glp-1, dopamine, VTA, hedonic-eating, reward-circuitry, neuroscience, obesity, behavioral-dichotomy, semaglutide]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content